Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0249 in Alzheimer's Disease
NCT00420420Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MK-0249 in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Nov 2006; status: completed.
02
Drugs
MK-0249
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00420420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00420420.